세계의 뇌종양 치료제 시장 규모 조사 및 예측 : 치료법별, 적응증별, 유통 채널별, 지역별 분석(2023-2030년)

Global Brain Tumor Drugs Market is valued at approximately USD 1.80 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.2% over the forecast period 2023-2030. Brain tumors are abnormal growths of cells that develop in the brain or nearby areas. Tumors that develop in the brain is the primary brain tumor and tumor that begin in other parts of the body is known as secondary or metastatic brain tumors. The size of the tumor varies from very small size to large size. The increasing prevalence of brain tumors is a major contributing factor to the growth of the market. However, the high cost of treatments hinder market expansion.

The rising prevalence of brain cancer due to changing lifestyle habits, rapid urbanization, and increasing rate of active smokers is driving the market growth. According to Globocan 2020 estimates, there were 308,102 new cases of brain cancer worldwide in 2021, resulting in 251,329 new deaths. According to the American Cancer Society, around 24,530 malignant brain or spinal cord tumors were diagnosed in 2021, with an additional 3,460 children under the age of 15 expected to be diagnosed with brain or CNS tumors this year. The European Society for Medical Oncology (ESMO) has adopted a neurosurgery protocol to slow down tumor progression and provide a longer survival time, according to a research study titled "Brain Tumor Management Amidst COVID-19 Pandemic" in August 2020. The growing concern for the disease and its treatment is driving the market, along with key players investing in research and development. Furthermore, increasing government initiatives to provide a conducive environment for drug approval and the rising number of pharmaceutical companies developing these drugs propel the market growth. However, the side effects associated with these drugs hinder market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Brain Tumor Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 due to proper reimbursement policies in the U.S. and the increasing launch of new drugs. Asia Pacific is expected to grow significantly over the forecast period, due to varying regulatory policies and rising awareness about cancer and its types. According to the Brain Tumor Research Organization, Australia has average rating of brain tumor care was the lowest of all cancers, with a score of 8.37 out of 10.

Major market player included in this report are:

• Johnson & Johnson Services, Inc.
• Bayer AG
• F. Hoffmann-La Roche Ltd
• Eisai Co. Ltd
• Novartis AG
• Merck & Co. Inc.
• Amgen Inc.
• AstraZeneca PLC,
• Pfizer, Inc.
• GlaxoSmithKline PLC

Recent Developments in the Market:

• In November 2021, Pfizer Inc. acquired Trillium Therapeutics, a clinical-stage immuno-oncology company that focuses primarily on developing innovative therapies for the treatment of cancer.
• In September 2022, F. Hoffmann-La Roche Ltd. acquired Good Therapeutics, to gain rights to Good Therapeutics' platform technology, which has applications in various fields such as autoimmune diseases, pain management, metabolic diseases, and cancer.

Global Brain Tumor Drugs Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Therapy, Indication, Distribution Channel, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy:

• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Others

By Indication:

• Pituitary
• Meningioma
• Glioma
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail & Online Pharmacy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Brain Tumor Drugs Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Brain Tumor Drugs Market, by Therapy, 2020-2030 (USD Billion)
  • 1.2.3. Brain Tumor Drugs Market, by Indication, 2020-2030 (USD Billion)
  • 1.2.4. Brain Tumor Drugs Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Brain Tumor Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Brain Tumor Drugs Market Dynamics

• 3.1. Brain Tumor Drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising prevalence of brain cancer cases
    • 3.1.1.2. Increasing awareness about the disease
    • 3.1.1.3. Strong R&D initiatives from strong players
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Therapy
    • 3.1.2.2. Side effects associated with the treatment
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Increasing government initiatives
    • 3.1.3.2. Increasing rate of pharmaceutical companies that are developing these drugs

Chapter 4. Global Brain Tumor Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Brain Tumor Drugs Market, by Therapy

• 5.1. Market Snapshot
• 5.2. Global Brain Tumor Drugs Market by Therapy, Performance - Potential Analysis
• 5.3. Global Brain Tumor Drugs Market Estimates & Forecasts by Therapy 2020-2030 (USD Billion)
• 5.4. Brain Tumor Drugs Market, Sub Segment Analysis
  • 5.4.1. Targeted Therapy
  • 5.4.2. Chemotherapy
  • 5.4.3. Immunotherapy
  • 5.4.4. Others

Chapter 6. Global Brain Tumor Drugs Market, by Indication

• 6.1. Market Snapshot
• 6.2. Global Brain Tumor Drugs Market by Indication, Performance - Potential Analysis
• 6.3. Global Brain Tumor Drugs Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
• 6.4. Brain Tumor Drugs Market, Sub Segment Analysis
  • 6.4.1. Pituitary
  • 6.4.2. Meningioma
  • 6.4.3. Glioma
  • 6.4.4. Others

Chapter 7. Global Brain Tumor Drugs Market, by Distribution Channel

• 7.1. Market Snapshot
• 7.2. Global Brain Tumor Drugs Market by Distribution Channel, Performance - Potential Analysis
• 7.3. Global Brain Tumor Drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 7.4. Brain Tumor Drugs Market, Sub Segment Analysis
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail & Online Pharmacy

Chapter 8. Global Brain Tumor Drugs Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Brain Tumor Drugs Market, Regional Market Snapshot
• 8.4. North America Brain Tumor Drugs Market
  • 8.4.1. U.S. Brain Tumor Drugs Market
    • 8.4.1.1. Therapy breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Indication breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Brain Tumor Drugs Market
• 8.5. Europe Brain Tumor Drugs Market Snapshot
  • 8.5.1. U.K. Brain Tumor Drugs Market
  • 8.5.2. Germany Brain Tumor Drugs Market
  • 8.5.3. France Brain Tumor Drugs Market
  • 8.5.4. Spain Brain Tumor Drugs Market
  • 8.5.5. Italy Brain Tumor Drugs Market
  • 8.5.6. Rest of Europe Brain Tumor Drugs Market
• 8.6. Asia-Pacific Brain Tumor Drugs Market Snapshot
  • 8.6.1. China Brain Tumor Drugs Market
  • 8.6.2. India Brain Tumor Drugs Market
  • 8.6.3. Japan Brain Tumor Drugs Market
  • 8.6.4. Australia Brain Tumor Drugs Market
  • 8.6.5. South Korea Brain Tumor Drugs Market
  • 8.6.6. Rest of Asia Pacific Brain Tumor Drugs Market
• 8.7. Latin America Brain Tumor Drugs Market Snapshot
  • 8.7.1. Brazil Brain Tumor Drugs Market
  • 8.7.2. Mexico Brain Tumor Drugs Market
• 8.8. Middle East & Africa Brain Tumor Drugs Market
  • 8.8.1. Saudi Arabia Brain Tumor Drugs Market
  • 8.8.2. South Africa Brain Tumor Drugs Market
  • 8.8.3. Rest of Middle East & Africa Brain Tumor Drugs Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Johnson & Johnson Services, Inc.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Bayer AG
  • 9.3.3. F. Hoffmann-La Roche Ltd
  • 9.3.4. Eisai Co. Ltd
  • 9.3.5. Novartis AG
  • 9.3.6. Merck & Co. Inc.
  • 9.3.7. Amgen Inc.
  • 9.3.8. AstraZeneca PLC,
  • 9.3.9. Pfizer, Inc.
  • 9.3.10. GlaxoSmithKline PLC

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption